Avenue Therapeutics (ATXI) Tops Q3 EPS by 34c

Avenue Therapeutics (NASDAQ: ATXI) reported Q3 EPS of $0.06, $0.34 better than the analyst estimate of ($0.28).

For earnings history and earnings-related data on Avenue Therapeutics (ATXI) click here.

You May Also Be Interested In

• McDonald’s said to plan value strategy overhaul to revive US sales growth
• Rexford Industrial closes $1.2B portfolio sale to EQT Real Estate
• Forgent Power Solutions, Inc. (FPS) Tops Q2 EPS by 1c, Beats on Revenue; Offers FY27 Guidance